Upgrade to Finviz Elite: Get our fastest platform speed, real-time data, and unlimited screening & charting. Start Free Trial

BMEA

Biomea Fusion Inc

1.32

Jul 10 • 04:00PM ET +0.01 (0.76%)

Healthcare Biotechnology USA Micro NASD

Peers: AARD AGEN CBUS CNTB GALT IMUX KZIA NTHI SPRO VRCA

| Held by: VTI VXF IWC BTEC CHNA

Scroll to Statements

Index	-
Market Cap	95.44M
Enterprise Value	51.62M
Income	-44.95M
Sales	0.00M
Book/sh	0.26
Cash/sh	0.62
Dividend Est.	-
Dividend TTM	-
Dividend Ex-Date	-
Dividend Gr. 3/5Y	- -
Payout	-
Employees	41
IPO	Apr 16, 2021

P/E	-
Forward P/E	-
PEG	-
P/S	-
P/B	5.10
P/C	2.12
P/FCF	-
EV/EBITDA	-
EV/Sales	-
Quick Ratio	4.98
Current Ratio	4.98
Debt/Eq	0.07
LT Debt/Eq	0.00
Option/Short	Yes / Yes

EPS (ttm)	-0.89
EPS next Y	-1.19
EPS next Q	-0.22
EPS this Y	25.99%
EPS next Y	-35.81%
EPS next 5Y	3.23%
EPS past 3/5Y	24.92% -46.26%
Sales past 3/5Y	- -
EPS Y/Y TTM	74.83%
Sales Y/Y TTM	-
EPS Q/Q	78.51%
Sales Q/Q	-
Earnings	May 11 AMC
EPS/Sales Surpr.	26.50% -

Insider Own	6.76%
Insider Trans	0.00%
Inst Own	39.57%
Inst Trans	1.23%
ROA	-88.62%
ROE	-189.44%
ROIC	-240.13%
Gross Margin	-
Oper. Margin	-
Profit Margin	-
SMA20	2.72%
SMA50	-1.95%
SMA200	-7.06%
Trades

Shs Outstand	72.30M
Shs Float	67.41M
Short Float	20.52%
Short Ratio	10.94
Short Interest	13.83M
52W High	2.99 -55.85%
52W Low	0.87 51.39%
Volatility	7.80% 7.41%
ATR (14)	0.11
RSI (14)	49.59
Beta	-0.31
Rel Volume	1.11
Avg Volume	1.26M
Volume	1,407,167

Perf Week	-6.38%
Perf Month	16.30%
Perf Quarter	-28.65%
Perf Half Y	-0.75%
Perf YTD	6.45%
Perf Year	-31.61%
Perf 3Y	-93.91%
Perf 5Y	-91.59%
Perf 10Y	-
Recom	1.50
Target Price	7.00
Prev Close	1.31
Price	1.32
Change	0.76%

Date	Action	Analyst	Rating Change	Price Target Change
Jan-13-26	Initiated	Rodman & Renshaw	Buy	$8
Aug-28-25	Initiated	Jefferies	Buy	$5
Jun-03-25	Resumed	Piper Sandler	Overweight	$7
Oct-09-24	Initiated	Edward Jones	Buy	$128
Sep-27-24	Upgrade	Truist	Hold → Buy	$54
Sep-27-24	Upgrade	Rodman & Renshaw	Neutral → Buy	$18
Aug-29-24	Initiated	CapitalOne	Overweight	$25
Jun-11-24	Downgrade	Truist	Buy → Hold
Jun-07-24	Downgrade	Barclays	Overweight → Equal Weight	$30 → $5
Apr-02-24	Downgrade	JP Morgan	Overweight → Neutral	$51 → $14
Feb-06-24	Initiated	Truist	Buy	$55
Jul-27-23	Initiated	Scotiabank	Sector Outperform	$41
Jun-26-23	Downgrade	Jefferies	Buy → Hold
May-12-23	Initiated	Barclays	Overweight	$50
Mar-29-23	Reiterated	Oppenheimer	Outperform	$25 → $47
Mar-28-23	Reiterated	H.C. Wainwright	Buy	$37 → $44
Feb-24-23	Initiated	Citigroup	Buy	$20
Jun-02-22	Resumed	H.C. Wainwright	Buy	$16
Jan-12-22	Initiated	H.C. Wainwright	Buy	$13
Dec-17-21	Initiated	Oppenheimer	Outperform	$22

Show Previous Ratings

Jun-05-26 07:32PM	Biomea Fusion Presents New Clinical and Translational Data for Icovamenib at the American Diabetes Association ("ADA") 86th Scientific Sessions and Announces Expansion of Ongoing Phase I BMF-650 Study (GlobeNewswire) -7.30% -9.45%
Jun-03-26 08:00AM	Biomea Fusion Announces Research Collaboration with University of Leicester to Evaluate Icovamenib in Combination with Semaglutide in Obesity (GlobeNewswire) -5.11%
May-12-26 04:05PM	Biomea Fusion to Participate at Upcoming Investor Conferences (GlobeNewswire) -6.33%
May-11-26 04:54PM	Biomea Fusion Reports First Quarter 2026 Financial Results and Corporate Highlights (GlobeNewswire)
May-05-26 05:50PM	Biomea Fusion Announces Poster Presentations of Icovamenib at the American Diabetes Association (ADA) 86th Scientific Sessions (GlobeNewswire) +5.26%
05:37PM	Loading…
Apr-27-26 05:37PM	Biomea Fusion Announces Positive 52-Week Results from Phase 2 COVALENT-112 Trial in Type 1 Diabetes Showing C-Peptide Improvement and Durability Following 12-Weeks of Icovamenib Treatment (GlobeNewswire) -8.47% -11.56%
Mar-31-26 07:00AM	Biomea Fusion Announces First Patient Dosed in Newly Initiated Phase II Programs Enrolling Type 2 Diabetes Patients Failing on Standard-of-Care Therapies (GlobeNewswire) +15.91%
Mar-24-26 04:05PM	Biomea Fusion Reports Full Year 2025 Financial Results and Corporate Highlights (GlobeNewswire) +7.96%
Mar-14-26 04:30AM	Biomea Fusion Presents Phase II COVALENT-111 Data in Type 2 Diabetes at the 19th International Conference on Advanced Technologies & Treatments for Diabetes 2026 (GlobeNewswire)
Feb-26-26 11:14PM	Biomea Fusion Spotlights Durable Diabetes Data, Oral GLP-1 Weight-Loss Program at Oppenheimer Conf. (MarketBeat) -5.52%
Feb-19-26 07:00AM	Biomea Fusion to Participate at Upcoming Investor Conferences (GlobeNewswire)
Jan-19-26 08:01AM	Rodman & Renshaw Initiates Biomea Fusion (BMEA) at Buy with $8 Price Target (Insider Monkey)
Jan-15-26 08:48AM	Biomea Fusion Spotlights Diabetes, Obesity Pipeline at JPMorgan Conference, Sets 2026 Milestones (MarketBeat) -13.89%
Jan-12-26 08:00AM	Biomea Fusion Enters 2026 Focused on Executing Key Icovamenib and BMF-650 Milestones (GlobeNewswire)
Dec-17-25 07:00AM	Biomea Fusion to Present at the 44th Annual J.P. Morgan Healthcare Conference (GlobeNewswire)
06:35PM	Loading…
Dec-09-25 06:35PM	Biomea Fusion Announces KOL Presentation and Interview on Menin and Icovamenib at WCIRDC 2025 (GlobeNewswire) +14.93%
Dec-05-25 07:00AM	Biomea Fusion Presents COVALENT-111 Study Results at the 23rd World Congress on Insulin Resistance, Diabetes & Cardiovascular Disease (WCIRDC) (GlobeNewswire)
Dec-01-25 04:10PM	Biomea Fusion Announces Oral Presentation of Icovamenib at the 23rd World Congress on Insulin Resistance, Diabetes & Cardiovascular Disease (WCIRDC) (GlobeNewswire) -7.34% -5.22%
04:05PM	Biomea Fusion, Inc. Reports Inducement Grant under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire)
Nov-24-25 07:00AM	Biomea Fusion to Participate at Upcoming Investor Conferences (GlobeNewswire)
Nov-10-25 07:00AM	Biomea Fusion to Participate at Jefferies London Healthcare Conference (GlobeNewswire)
Nov-05-25 07:00AM	Biomea Fusion Showcases Preclinical Advances for BMF-650 and Icovamenib with Low Dose Semaglutide at ObesityWeek 2025 (GlobeNewswire) +6.35%
Nov-04-25 04:05PM	Biomea Fusion Reports Third Quarter 2025 Financial Results and Corporate Highlights (GlobeNewswire)
Oct-30-25 08:00AM	Biomea Fusion to Present Poster Presentations at ObesityWeek2025 (GlobeNewswire)
Oct-27-25 08:00AM	Biomea Fusion Announces First Patient Dosed in Phase I Study of BMF-650 a Next-Generation Oral GLP-1 Receptor Agonist (GlobeNewswire)
Oct-21-25 07:05PM	Biomea Fusion to Participate in Citi's SMID Biotech C-Suite Fireside Chat Series (GlobeNewswire) -9.43%
Oct-07-25 08:00AM	Biomea Fusion Announces Pricing of Public Offering of Securities (GlobeNewswire) -30.90%
Oct-06-25 04:18PM	Biomea Fusion Announces Proposed Public Offering of Securities (GlobeNewswire) +24.19%
04:03PM	Biomea Fusion Announces Positive 52-Week Results from Phase II COVALENT-111 Study in Type 2 Diabetes Demonstrating Non-Chronic Treatment with Icovamenib Benefits Two Distinct Patient Populations (GlobeNewswire)
Oct-01-25 07:00AM	Biomea Fusion, Inc. Reports Inducement Grant under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire)
07:00AM	Loading…
Sep-16-25 07:00AM	Biomea Fusion Presents Data Demonstrating Enhanced Preclinical Activity of Icovamenib in Combination with Semaglutide in Type 2 Diabetes (T2D) Animal Model at the 61st EASD Annual Meeting and Provides Additional Corporate Update (GlobeNewswire)
Aug-28-25 09:39AM	Five Below upgraded, Bill downgraded: Wall Street's top analyst calls (The Fly)
Aug-05-25 04:05PM	Biomea Fusion Reports Second Quarter 2025 Financial Results and Corporate Highlights (GlobeNewswire)
Jul-24-25 07:00AM	Biomea Fusion Appoints Julianne Averill to its Board of Directors (GlobeNewswire)
Jun-24-25 01:07PM	Biomea Fusion announces presentation of icovamenib preclinical, clinical data (TipRanks) +11.24%
Jun-23-25 07:00AM	Biomea Fusion Presents New Preclinical and Clinical Data on Icovamenib at the 85th Scientific Sessions of the American Diabetes Association (ADA) (GlobeNewswire) -6.63%
Jun-18-25 07:00AM	Biomea Fusion Reports Preclinical Data for BMF-650, a Next-Generation Oral GLP-1 Receptor Agonist Candidate, Demonstrating Robust Weight Loss and Appetite Suppression in Obese Non-Human Primates (GlobeNewswire) -34.14%
Jun-17-25 11:15PM	Biomea Fusion Announces Pricing of Public Offering of Securities (GlobeNewswire) +10.27%
04:33PM	Biomea Fusion Announces Proposed Public Offering of Securities (GlobeNewswire)
Jun-13-25 06:45AM	Biomea Fusion Presents Updated Preliminary Clinical Data for Covalent FLT3 Inhibitor BMF-500 in Relapsed or Refractory Acute Leukemia at EHA 2025 (GlobeNewswire) -9.58%
Jun-03-25 12:00PM	Biomea Fusion (BMEA) Upgraded to Buy: Here's What You Should Know (Zacks) +60.65%
May-14-25 04:05PM	Biomea Fusion's BMF-500 Selected for Poster Presentation at EHA 2025 Highlighting Phase I Data in Relapsed/Refractory Acute Leukemia (GlobeNewswire) -10.43%
May-05-25 04:05PM	Biomea Fusion Reports First Quarter 2025 Financial Results and Corporate Highlights (GlobeNewswire) -8.26% -16.50%
Apr-02-25 09:35AM	After Plunging -27.9% in 4 Weeks, Here's Why the Trend Might Reverse for Biomea Fusion (BMEA) (Zacks) +8.54%
Apr-01-25 04:01PM	Biomea Fusion, Inc. Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire) -6.57%
09:35AM	After Plunging -19.32% in 4 Weeks, Here's Why the Trend Might Reverse for Biomea Fusion (BMEA) (Zacks)
Mar-31-25 04:10PM	Biomea Fusion Reports Fourth Quarter and Full Year 2024 Financial Results and Corporate Highlights (GlobeNewswire) -7.39%
09:35AM	After Plunging -20.42% in 4 Weeks, Here's Why the Trend Might Reverse for Biomea Fusion (BMEA) (Zacks)
Mar-25-25 07:00PM	Biomea Fusion Announces Leadership Transition (GlobeNewswire) -6.32%
08:50AM	Biomea Fusion announces presentation of icovamenib preclinical, clinical data (TipRanks)
Mar-24-25 08:30AM	Icovamenib Treatment in Patients with Severe Insulin-Deficient Diabetes Led to a Significant Improvement in Pancreatic Beta-cell Function with a 53% Mean Increase in C-peptide Levels 3 Months After Last Dose (GlobeNewswire)
Mar-03-25 08:00AM	Biomea Fusion, Inc. Reports Inducement Grant under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire) -8.65%
Feb-27-25 08:00AM	Biomea Fusion to Unveil New Icovamenib Data at the 18th International Conference on Advanced Technologies & Treatments for Diabetes (GlobeNewswire)
Jan-13-25 09:00AM	Biomea Fusion to Become a Diabetes and Obesity Medicines Company (GlobeNewswire)
09:00AM	Biomea Fusion to Become a Diabetes & Obesity Medicines Company (GlobeNewswire)
Jan-07-25 09:00AM	Biomea Fusion Reports New Preclinical Data on Icovamenib-Semaglutide Combination Study (GlobeNewswire)
Jan-06-25 09:04AM	Heres Why Biomea Fusion, Inc. (NASDAQ:BMEA) Is Among the Best Diabetes Stocks to Buy Under $10 (Insider Monkey) +5.09%
07:00AM	Biomea Fusion to Present at the 43rd Annual J.P. Morgan Healthcare Conference (GlobeNewswire)
Dec-17-24 10:41AM	Why Is Diabetes-Drug Developer Biomea Fusion Stock Trading Lower On Tuesday? (Benzinga) -20.68%
08:10AM	Biomea Fusion Announces Positive Topline Results from Ongoing Phase II COVALENT-111 Study in Patients with Type 2 Diabetes (GlobeNewswire)
Dec-16-24 06:15PM	Biomea Fusion to Host Conference Call to Announce Topline Results from Phase II COVALENT-111 Study in Patients with Type 2 Diabetes (T2D) (GlobeNewswire)
Dec-12-24 05:02PM	Biomea Fusion Announces Oral and Poster Presentations of Icovamenib at the 22nd World Congress on Insulin Resistance, Diabetes and Cardiovascular Disease (WCIRDC) (GlobeNewswire) -5.54%
05:02PM	Biomea Fusion Announces Oral and Poster Presentations of Icovamenib at the 22nd World Congress on Insulin Resistance, Diabetes & Cardiovascular Disease (WCIRDC) (GlobeNewswire)
Dec-09-24 04:01PM	Biomea Fusion Announces Preliminary Data from Ongoing COVALENT-103 Study of Investigational Covalent FLT3 Inhibitor BMF-500 in Relapsed or Refractory Acute Leukemia (GlobeNewswire) -5.08%
Dec-06-24 08:00AM	Biomea Fusion to Host Conference Call to Present initial Clinical Data from Phase I COVALENT-103 Study of BMF-500, a Covalent FLT3 Inhibitor, in Relapsed or Refractory Acute Leukemia (GlobeNewswire)
Dec-02-24 04:05PM	Biomea Fusion, Inc. Reports Inducement Grant under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire) -5.50%
Nov-18-24 08:00AM	Late-Breaker Oral Presentation Showing New Analysis from the Escalation Portion of COVALENT-111 Presented at the 1st Annual Asian Conference on Innovative Therapies for Diabetes Management (ATTD-ASIA 2024) (GlobeNewswire)
Nov-01-24 04:05PM	Biomea Fusion, Inc. Reports Inducement Grant under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire)
Oct-30-24 04:00PM	Biomea Fusion Presents Preclinical Data Showing Icovamenib (BMF-219) Enhanced Effectiveness of GLP-1-Based Therapies and Introduces BMF-650, a Next-Generation, Oral Small-Molecule GLP-1 Receptor Agonist Candidate (GlobeNewswire) -14.26% -9.38%
Oct-29-24 04:46PM	Biomea Fusion Reports Third Quarter 2024 Financial Results and Corporate Highlights (GlobeNewswire)
Oct-21-24 09:00AM	Biomea Fusion Announces Approval of icovamenib as International Nonproprietary Name for BMF-219 (GlobeNewswire)
Oct-15-24 04:05PM	Biomea Fusion to Host Conference Call and Webcast on Wednesday, October 30th at 4:30 pm ET to Announce Our Lead Clinical Candidate, BMF-650, a Next-Generation, Oral Small-Molecule GLP-1 Receptor Agonist and Preclinical Data Combining BMF-219 with a GLP-1 RA-Based Therapy (GlobeNewswire) +5.38%
Oct-10-24 08:57AM	Morning Movers: Arcadium Lithium surges after deal to be acquired (TipRanks)
Oct-07-24 09:00AM	Biomea Fusion to Present at the 1st Annual Asian Conference on Innovative Therapies for Diabetes Management (ATTD-ASIA 2024) (GlobeNewswire)
Oct-01-24 09:00AM	Biomea Announces Formation of Global Scientific Advisory Board with 22 World-Renowned Diabetes Experts (GlobeNewswire) -5.94%
Sep-27-24 12:20PM	FDA Removes Clinical Hold On Biomea Fusion's Early-Stage Trials For Potential Diabetes Candidate (Benzinga)
11:13AM	Biomeas stock bounces back as FDA lifts clinical hold on diabetes trials (Pharmaceutical Technology)
Sep-26-24 02:00PM	FDA Lifts Clinical Hold on BMF-219 in Type 2 and Type 1 Diabetes Trials (GlobeNewswire) +9.12%
Aug-14-24 09:55AM	Wall Street Analysts Think Biomea Fusion (BMEA) Could Surge 317.86%: Read This Before Placing a Bet (Zacks)
Aug-01-24 04:05PM	Biomea Fusion, Inc. Reports Inducement Grant under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire)
Jul-31-24 10:54PM	BMEA Stock Earnings: Biomea Fusion Beats EPS for Q2 2024 (InvestorPlace)
04:05PM	Biomea Fusion Reports Second Quarter 2024 Financial Results and Corporate Highlights (GlobeNewswire)
Jun-29-24 08:32PM	Biomea Fusion, Inc. (BMEA): Why Did Analysts Give This Biotech Penny Stock a Moderate Buy Rating? (Insider Monkey)
06:30PM	10 Best Biotech Penny Stocks to Buy Now (Insider Monkey)
Jun-28-24 02:21AM	Why Are Hedge Funds Shorting Biomea Fusion, Inc. (BMEA)? (Insider Monkey)
Jun-26-24 11:08PM	What Is Short Selling In Stock Market? 15 Stocks Hedge Funds are Shorting (Insider Monkey) -14.59%
Jun-17-24 09:00AM	Acute Myeloid Leukemia is on the Rise as Biotechs Race to Develop Groundbreaking Therapies (GlobeNewswire) -9.75%
Jun-11-24 11:34AM	Biomea Fusion, Inc. (NASDAQ:BMEA) Downgraded by Barclays (Insider Monkey)
09:06AM	Analysts on Wall Street Lower Ratings for These 10 Stocks (Insider Monkey)
Jun-07-24 04:23PM	Biomea Fusion Crashes 63% After FDA Puts Diabetes Treatment Studies On Hold (Investor's Business Daily) -63.27%
08:16AM	Why Is Biomea Fusion (BMEA) Stock Down 63% Today? (InvestorPlace)
07:22AM	Today's Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Friday (InvestorPlace)
06:17AM	Ride the Gamma Wave: 3 Stocks on the Verge of a Short Squeeze (InvestorPlace)
04:25AM	FDA places full clinical hold on Biomea Fusions diabetes trials of BMF-219 (Clinical Trials Arena)
Jun-06-24 04:05PM	Biomea Fusion Announces BMF-219 in Diabetes Placed on Clinical Hold (GlobeNewswire)
01:14PM	Short Squeeze Specialists: 3 Stocks With the Expertise to Defy Bearish Expectations (InvestorPlace)
Jun-03-24 04:05PM	Biomea Fusion, Inc. Reports Inducement Grant under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire)
May-30-24 09:12AM	Biomea Fusion Announces Completion of Enrollment of First 3 Arms in Phase 2 Expansion Cohorts of COVALENT-111 Study for BMF-219 in Type 2 Diabetes (GlobeNewswire)
May-02-24 10:54PM	BMEA Stock Earnings: Biomea Fusion Misses EPS for Q1 2024 (InvestorPlace)
04:05PM	Biomea Fusion Reports First Quarter 2024 Financial Results and Corporate Highlights (GlobeNewswire)

Biomea Fusion, Inc. is a biopharmaceutical company, which engages in the discovery, development, and commercialization of covalent small molecule drugs to treat patients with genetically defined cancers and metabolic disorders, such as diabetes. It offers its lead product candidate, BMF-219, an orally bioavailable, potent, and selective covalent inhibitor of menin, a transcriptional regulator known to play a direct role in oncogenic signaling in multiple cancers. The company was founded by Thomas Butler and Ramses Erdtmann in August 2017 and is headquartered in San Carlos, CA.

Interim CEO & DirectorDr. Michael J. M. Hitchcock Ph.D.

Co-FounderMr. Ramses M. Erdtmann

Chief Technical & Quality OfficerMr. Heow Tan

Senior Vice President of LegalCaroline Perez- Dupont J.D.

Executive Vice President of ResearchDr. Thorsten Kirschberg Ph.D.

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
Erdtmann Rainer M	See Remarks	Dec 11 '25	Buy	1.43	30,000	42,999	723,027	Dec 15 04:15 PM
Hitchcock Michael J.M.	Interim CEO	Dec 02 '25	Buy	0.99	100,000	99,180	115,000	Dec 04 04:15 PM
Erdtmann Rainer M	See Remarks	Nov 28 '25	Buy	1.10	40,000	44,052	683,027	Dec 02 04:15 PM
Erdtmann Rainer M	See Remarks	Dec 01 '25	Buy	1.05	10,000	10,500	693,027	Dec 02 04:15 PM

open in yahoo | open in reuters | open in marketwatch | open in google | open in EDGAR

BMEA

Biomea Fusion Inc

Upgrade your Finviz experience